![George C. Hillman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
George C. Hillman
Geen lopende functies
Loopbaan van George C. Hillman
Eerdere bekende functies van George C. Hillman
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Pintex Pharmaceuticals, Inc.
![]() Pintex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pintex Pharmaceuticals, Inc. used to discover and develop cancer therapeutics. The company used to discover and commercialize new antibiotics focused on drug resistance. Pintex Pharmaceuticals was founded by Walter Gilbert, Kung Ping Lu and Janusz Sowadski in 1999 and was headquartered in Watertown, MA. | President | 01-01-2003 | 01-01-2006 |
Treasurer | 01-01-2003 | 01-01-2006 | |
Cohesive Technologies, Inc.
![]() Cohesive Technologies, Inc. Chemicals: Major DiversifiedProcess Industries Cohesive Technologies, Inc. designs, manufactures, and markets liquid chromatography solutions. It serves to the drug discovery, pharmaceutical, contract research, and clinical diagnostic industries. The company was founded in 1991 and is headquartered in Franklin, MA. | Operationeel Directeur | 01-01-1991 | 01-01-1997 |
Viracta Subsidiary, Inc.
![]() Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Oprichter | 01-01-2007 | - |
Paratek Pharmaceuticals, Inc. /Old/
![]() Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | Operationeel Directeur | 01-01-1997 | - |
Pricewaterhouse & Co. | Corporate Officer/Principal | - | - |
HemaQuest Pharmaceuticals, Inc.
![]() HemaQuest Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology HemaQuest Pharmaceuticals, Inc. develops small molecule therapeutics. Its products include hydroxyurea, a therapeutic agent for the treatment of underlying pathology of sickle cell anemia and for the treatments of beta thalassemia, sickle cell anemia, neutropenia, and various hematological disorders. The company was founded by Ronald J. Berenson, Douglas V. Faller, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos and Robert Williams in October 2007 and is headquartered in San Diego, CA. | Operationeel Directeur | 01-10-2007 | - |
Oprichter | 26-08-2009 | - |
Opleiding van George C. Hillman
Rutgers State University of New Jersey | Masters Business Admin |
Gannon University | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 8 |
Frankrijk | 2 |
Operationeel
Chief Operating Officer | 3 |
Founder | 2 |
Masters Business Admin | 1 |
Sectoraal
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 6 |
---|---|
HemaQuest Pharmaceuticals, Inc.
![]() HemaQuest Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology HemaQuest Pharmaceuticals, Inc. develops small molecule therapeutics. Its products include hydroxyurea, a therapeutic agent for the treatment of underlying pathology of sickle cell anemia and for the treatments of beta thalassemia, sickle cell anemia, neutropenia, and various hematological disorders. The company was founded by Ronald J. Berenson, Douglas V. Faller, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos and Robert Williams in October 2007 and is headquartered in San Diego, CA. | Health Technology |
Pricewaterhouse & Co. | Commercial Services |
Cohesive Technologies, Inc.
![]() Cohesive Technologies, Inc. Chemicals: Major DiversifiedProcess Industries Cohesive Technologies, Inc. designs, manufactures, and markets liquid chromatography solutions. It serves to the drug discovery, pharmaceutical, contract research, and clinical diagnostic industries. The company was founded in 1991 and is headquartered in Franklin, MA. | Process Industries |
Paratek Pharmaceuticals, Inc. /Old/
![]() Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | Health Technology |
Pintex Pharmaceuticals, Inc.
![]() Pintex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pintex Pharmaceuticals, Inc. used to discover and develop cancer therapeutics. The company used to discover and commercialize new antibiotics focused on drug resistance. Pintex Pharmaceuticals was founded by Walter Gilbert, Kung Ping Lu and Janusz Sowadski in 1999 and was headquartered in Watertown, MA. | Health Technology |
Viracta Subsidiary, Inc.
![]() Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
- Beurs
- Insiders
- George C. Hillman
- Ervaring